Indian IP Bill Would Give Drug Inventor, Institution Shares Of Patent Profits
This article was originally published in PharmAsia News
Pharmaceutical scientists and others are expected to benefit as well as the institutions they work for under a bill under review by the Indian government. A draft of the intellectual property measure proposes a system similar to that of the United States, which allows public institutions to patent inventions and enter into commercial ventures to market the work. The proposal, which India's Cabinet is to decide whether to introduce in Parliament, would have the inventor of the patentable product to receive 30 percent of market revenue, with 10 percent allocated to the institution where the work was produced. (Click here for more
You may also be interested in...
Third quarter earnings show Gilead’s Immunomedics buy paid off, but filgotinib’s path may narrow. The HIV and HCV franchises picked up from their COVID-19 lull.
US pharmacy group says that 10 to 12 states have indicated through an informal survey that they do not have the manpower or funding to implement the US FDA’s final MOU on inordinate compounding. They say what is at stake in these states is patient access to compounded medicines.
Mayo Clinic announces AI-based partnerships with Google and voice-analysis company Vocalis Health this week.